nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

03.08.2020 | Review

Unilateral cystectomy and serous histology are associated with relapse in borderline ovarian tumor patients with fertility-sparing surgery: a systematic review and meta-analysis

verfasst von: Na Li, Xiu Ming, Zhengyu Li

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Surgical procedures, histological subtypes, and surgical approaches are involved in the recurrence of borderline ovarian tumors (BOTs), but whether those three factors affect relapse remains controversial. This study aimed to explore the effects of surgical procedures, histological subtypes, and surgical approaches on the relapse and pregnancy rates of BOT after fertility-preserving surgery (FPS) according to the patients’ characteristics.

Methods

A systematic search of PubMed, Embase, and the Cochrane library was conducted from their inception to November 2018. Studies that investigated the impact of surgical procedures, histological subtypes, and surgical approaches on the relapse and pregnancy rates in patients with BOT after FPS were eligible. The pooled odds ratios (ORs) with the corresponding 95% confidence intervals (CIs) were calculated using the random-effects model.

Results

Thirty-five studies involving a total of 2921 patients with BOT after FPS were included. The pooled ORs indicated that the risk of relapse was significantly increased in patients who underwent unilateral cystectomy or with serous BOT. There was no significant difference between laparoscopy and laparotomy on the risk of relapse. Surgical procedures, histological subtypes, and surgical approaches did not influence pregnancy rates.

Conclusions

Patients who underwent unilateral cystectomy or with serous BOT presented an excess risk of relapse after FPS, but the surgical approach did not affect the risk of relapse. The pregnancy rate is not affected by surgical procedures, histological subtypes, and surgical approaches.

Nur mit Berechtigung zugänglich

Trillsch F, Ruetzel JD, Herwig U, Doerste U, Woelber L, Grimm D, Choschzick M, Jaenicke F, Mahner S (2013) Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT). J Ovarian Res 6(1):48. https://doi.org/10.1186/1757-2215-6-48CrossRefPubMedPubMedCentral

Taylor HC (1929) Malignant and semimalignant tumors of the ovary. Surg Gynecol Obstet 48:204–230

Seidman JD, Soslow RA, Vang R, Berman JJ, Stoler MH, Sherman ME, Oliva E, Kajdacsy-Balla A, Berman DM, Copeland LJ (2004) Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol 35(8):918–933CrossRef

Serov SF, Scully RE, Sobin LH (1973) Histologic typing of ovarian tumors in international histologic classification of tumors, vol 9. World Health Organization, Geneva

Morice P (2006) Borderline tumours of the ovary and fertility. Eur J Cancer (Oxf, Engl: 1990) 42(2):149–158. https://doi.org/10.1016/j.ejca.2005.07.029CrossRef

Akeson M, Zetterqvist BM, Dahllof K, Jakobsen AM, Brannstrom M, Horvath G (2008) Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 18(3):453–459. https://doi.org/10.1111/j.1525-1438.2007.01051.xCrossRef

Vasconcelos I, de Sousa Mendes M (2015) Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk. Eur J Cancer (Oxf, Engl: 1990) 51(5):620–631. https://doi.org/10.1016/j.ejca.2015.01.004CrossRef

Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, de Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Kommoss F, Hauptmann S, du Bois A (2014) Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. Ann Oncol Off J Eur Soc Med Oncol 25(7):1320–1327. https://doi.org/10.1093/annonc/mdu119CrossRef

Novikova EG, Shevchuk AS (2014) Organ-sparing therapy for patients with borderline ovarian tumors. Vopr Onkol 60(3):267–273PubMed

10.

Karlsen NMS, Karlsen MA, Hogdall E, Nedergaard L, Christensen IJ, Hogdall C (2016) Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). Gynecol Oncol 142(1):50–53. https://doi.org/10.1016/j.ygyno.2016.05.005CrossRefPubMed

11.

Morris RT, Gershenson DM, Silva EG, Follen M, Morris M, Wharton JT (2000) Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol 95(4):541–547PubMed

12.

Fischerova D, Zikan M, Dundr P, Cibula D (2012) Diagnosis, treatment, and follow-up of borderline ovarian tumors. Oncologist 17(12):1515–1533. https://doi.org/10.1634/theoncologist.2012-0139CrossRefPubMedPubMedCentral

13.

Vancraeynest E, Moerman P, Leunen K, Amant F, Neven P, Vergote I (2016) Fertility preservation is safe for serous borderline ovarian tumors. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 26(8):1399–1406. https://doi.org/10.1097/igc.0000000000000782CrossRef

14.

Helpman L, Yaniv A, Beiner ME, Aviel-Ronen S, Perri T, Ben-Baruch G, Hogen Ben-David L, Jakobson-Setton A, Korach J (2017) Fertility preservation in women with borderline ovarian tumors—how does it impact disease outcome? A cohort study. Acta Obstet Gynecol Scand 96(11):1300–1306. https://doi.org/10.1111/aogs.13203CrossRefPubMed

15.

Romeo M, Pons F, Barretina P, Radua J (2013) Incomplete staging surgery as a major predictor of relapse of borderline ovarian tumor. World J Surg Oncol 11:13. https://doi.org/10.1186/1477-7819-11-13CrossRefPubMedPubMedCentral

16.

Ricciardi E, Baert T, Ataseven B, Heitz F, Prader S, Bommert M, Schneider S, du Bois A, Harter P (2018) Low-grade serous ovarian carcinoma. Geburtshilfe Frauenheilkd 78(10):972–976. https://doi.org/10.1055/a-0717-5411CrossRefPubMedPubMedCentral

17.

Prat J, De Nictolis M (2002) Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol 26(9):1111–1128CrossRef

18.

Deavers MT, Gershenson DM, Tortolero-Luna G, Malpica A, Lu KH, Silva EG (2002) Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. Am J Surg Pathol 26(9):1129–1141CrossRef

19.

Morice P, Camatte S, Rey A, Atallah D, Lhomme C, Pautier P, Pomel C, Cote JF, Haie-Meder C, Duvillard P, Castaigne D (2003) Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol Off J Eur Soc Med Oncol 14(4):592–598CrossRef

20.

Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR (2005) Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or = 5-year) follow-up. Am J Surg Pathol 29(6):707–723CrossRef

21.

Wu TI, Lee CL, Wu MY, Hsueh S, Huang KG, Yeh CJ, Lai CH (2009) Prognostic factors predicting recurrence in borderline ovarian tumors. Gynecol Oncol 114(2):237–241. https://doi.org/10.1016/j.ygyno.2009.05.018CrossRefPubMed

22.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012CrossRef

23.

Wells MG, Shea BO, Connell D (2009) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed Nov 2018

24.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRef

25.

Ades AE, Lu G, Higgins JP (2005) The interpretation of random-effects meta-analysis in decision models. Med Decis Mak Int J Soc Med Decis Mak 25(6):646–654. https://doi.org/10.1177/0272989x05282643CrossRef

26.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed) 327(7414):557–560. https://doi.org/10.1136/bmj.327.7414.557CrossRef

27.

Tobias A (1999) Assessing the influence of a single study in meta-analysis. Stata Tech Bull 47:15–17

28.

Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21(11):1559–1573. https://doi.org/10.1002/sim.1187CrossRefPubMed

29.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res Ed) 315(7109):629–634CrossRef

30.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRef

31.

Ji H, Yliskoski M, Anttila M, Syrjanen K, Saarikoski S (1996) Management of stage-I borderline ovarian tumors. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet 54(1):37–44CrossRef

32.

Tamakoshi K, Kikkawa F, Nakashima N, Tamakoshi A, Kawai M, Furuhashi Y, Hattori SE, Kuzuya K, Arii Y, Suganuma N, Tomoda Y (1997) Clinical behavior of borderline ovarian tumors: a study of 150 cases. J Surg Oncol 64(2):147–152CrossRef

33.

Beiner ME, Gotlieb WH, Davidson B, Kopolovic J, Ben-Baruch G (2001) Infertility treatment after conservative management of borderline ovarian tumors. Cancer 92(2):320–325CrossRef

34.

Morice P, Camatte S, El Hassan J, Pautier P, Duvillard P, Castaigne D (2001) Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 75(1):92–96CrossRef

35.

Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C (2001) Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol Off J Am Soc Clin Oncol 19(10):2658–2664. https://doi.org/10.1200/jco.2001.19.10.2658CrossRef

36.

Boran N, Cil AP, Tulunay G, Ozturkoglu E, Koc S, Bulbul D, Kose MF (2005) Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol 97(3):845–851. https://doi.org/10.1016/j.ygyno.2005.03.010CrossRefPubMed

37.

Rao GG, Skinner EN, Gehrig PA, Duska LR, Miller DS, Schorge JO (2005) Fertility-sparing surgery for ovarian low malignant potential tumors. Gynecol Oncol 98(2):263–266. https://doi.org/10.1016/j.ygyno.2005.04.025CrossRefPubMed

38.

Suh-Burgmann E (2006) Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol 103(3):841–847. https://doi.org/10.1016/j.ygyno.2006.05.014CrossRefPubMed

39.

Poncelet C, Fauvet R, Boccara J, Darai E (2006) Recurrence after cystectomy for borderline ovarian tumors: results of a French multicenter study. Ann Surg Oncol 13(4):565–571. https://doi.org/10.1245/aso.2006.12.024CrossRefPubMed

40.

Romagnolo C, Gadducci A, Sartori E, Zola P, Maggino T (2006) Management of borderline ovarian tumors: results of an Italian multicenter study. Gynecol Oncol 101(2):255–260. https://doi.org/10.1016/j.ygyno.2005.10.014CrossRefPubMed

41.

Yokoyama Y, Moriya T, Takano T, Shoji T, Takahashi O, Nakahara K, Yamada H, Yaegashi N, Okamura K, Izutsu T, Sugiyama T, Tanaka T, Kurachi H, Sato A, Tase T, Mizunuma H (2006) Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br J Cancer 94(11):1586–1591. https://doi.org/10.1038/sj.bjc.6603139CrossRefPubMedPubMedCentral

42.

Tinelli FG, Tinelli R, La Grotta F, Tinelli A, Cicinelli E, Schonauer MM (2007) Pregnancy outcome and recurrence after conservative laparoscopic surgery for borderline ovarian tumors. Acta Obstet Gynecol Scand 86(1):81–87. https://doi.org/10.1080/00016340600994596CrossRefPubMed

43.

Wong HF, Low JJ, Chua Y, Busmanis I, Tay EH, Ho TH (2007) Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 17(2):342–349. https://doi.org/10.1111/j.1525-1438.2007.00864.xCrossRef

44.

Yinon Y, Beiner ME, Gotlieb WH, Korach Y, Perri T, Ben-Baruch G (2007) Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors. Fertil Steril 88(2):479–484. https://doi.org/10.1016/j.fertnstert.2006.11.128CrossRefPubMed

45.

De Iaco P, Ferrero A, Rosati F, Melpignano M, Biglia N, Rolla M, De Aloysio D, Sismondi P (2009) Behaviour of ovarian tumors of low malignant potential treated with conservative surgery. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 35(6):643–648. https://doi.org/10.1016/j.ejso.2008.09.011CrossRef

46.

Kokawa K, Mikami Y, Sakata H, Oki N, Tanakas T, Yamazaki M, Nakata Y, Umesaki N (2009) Clinical outcome and prognostic factors in borderline tumors of the ovary. Results from 17 years’ experience in the Kinki District of Japan (1990–2006). Eur J Gynaecol Oncology 30(2):155–161

47.

Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH (2009) Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery. Gynecol Oncol 113(1):75–82. https://doi.org/10.1016/j.ygyno.2008.12.034CrossRefPubMed

48.

Benito V, Lubrano A, Arencibia O, Medina N, Álvarez Eva E, Andújar M, Falcón Juan M, Falcón O (2010) Serous and mucinous borderline ovarian tumors: are there real differences between these two entities? Eur J Obstet Gynecol Reprod Biol 153(2):188–192. https://doi.org/10.1016/j.ejogrb.2010.07.024CrossRefPubMed

49.

Uzan C, Kane A, Rey A, Gouy S, Duvillard P, Morice P (2010) Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary. Ann Oncol Off J Eur Soc Med Oncol 21(1):55–60. https://doi.org/10.1093/annonc/mdp267CrossRef

50.

Kanat-Pektas M, Ozat M, Gungor T, Dikici T, Yilmaz B, Mollamahmutoglu L (2011) Fertility outcome after conservative surgery for borderline ovarian tumors: a single center experience. Arch Gynecol Obstet 284(5):1253–1258. https://doi.org/10.1007/s00404-010-1804-7CrossRefPubMed

51.

Anfinan N, Sait K, Ghatage P, Nation J, Chu P (2011) Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre. Arch Gynecol Obstet 284(3):731–735. https://doi.org/10.1007/s00404-010-1713-9CrossRefPubMed

52.

Khunamornpong S, Settakorn J, Sukpan K, Suprasert P, Siriaunkgul S (2011) Mucinous tumor of low malignant potential (“borderline” or “atypical proliferative” tumor) of the ovary: a study of 171 cases with the assessment of intraepithelial carcinoma and microinvasion. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol 30(3):218–230. https://doi.org/10.1097/PGP.0b013e3181fcf01aCrossRef

53.

Song T, Hun Choi C, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG (2011) Oncologic and reproductive outcomes of cystectomy compared with oophorectomy as a treatment for borderline ovarian tumours. Hum Reprod (Oxf, Engl) 26(8):2008–2014. https://doi.org/10.1093/humrep/der119CrossRef

54.

Tsai HW, Ko CC, Yeh CC, Chen YJ, Twu NF, Chao KC, Yen MS (2011) Unilateral salpingo-oophorectomy as fertility-sparing surgery for borderline ovarian tumors. J Chin Med Assoc 74(6):250–254. https://doi.org/10.1016/j.jcma.2011.04.003CrossRefPubMed

55.

Ferrero A, Strada I, Di Marcoberardino B, Maccarini LR, Pozzati F, Rossi M, Biglia N, De Iaco P (2012) Clinical significance of microinvasion in borderline ovarian tumors and its impact on surgical management. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 22(7):1158–1162. https://doi.org/10.1097/IGC.0b013e31825e5254CrossRef

56.

Uzan C, Muller E, Kane A, Rey A, Gouy S, Bendiffallah S, Duvillard P, Fauvet R, Darai E, Morice P (2014) Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary. Ann Oncol Off J Eur Soc Med Oncol 25(1):166–171. https://doi.org/10.1093/annonc/mdt430CrossRef

57.

Chen RF, Li J, Zhu TT, Yu HL, Lu X (2016) Fertility-sparing surgery for young patients with borderline ovarian tumors (BOTs): single institution experience. J Ovarian Res 9:16. https://doi.org/10.1186/s13048-016-0226-yCrossRefPubMedPubMedCentral

58.

Ureyen I, Karalok A, Tasci T, Turkmen O, Boran N, Tulunay G, Turan T (2016) The factors predicting recurrence in patients with serous borderline ovarian tumor. Int J Gynecol Cancer Off J Inte Gynecol Cancer Soc 26(1):66–72. https://doi.org/10.1097/igc.0000000000000568CrossRef

59.

Chang C, Chen J, Chen WA, Ho SP, Liou WS, Chiang AJ (2017) Assessing the risk of clinical and pathologic factors for relapse of borderline ovarian tumours. J Obstet Gynaecol J Inst Obstet Gynaecol 37(2):233–237. https://doi.org/10.1080/01443615.2016.1244810CrossRef

60.

Chen X, Fang C, Zhu T, Zhang P, Yu A, Wang S (2017) Identification of factors that impact recurrence in patients with borderline ovarian tumors. J Ovarian Res 10(1):23. https://doi.org/10.1186/s13048-017-0316-5CrossRefPubMedPubMedCentral

61.

Lee SY, Choi MC, Kwon BR, Jung SG, Park H, Joo WD, Lee C, Lee JH, Lee JM (2017) Oncologic and obstetric outcomes of conservative surgery for borderline ovarian tumors in women of reproductive age. Obstet Gynecol Sci 60(3):289–295. https://doi.org/10.5468/ogs.2017.60.3.289CrossRefPubMedPubMedCentral

62.

Fang C, Zhao L, Chen X, Yu A, Xia L, Zhang P (2018) The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (≤ 40 years old) with borderline ovarian tumors. BMC Cancer 18(1):1147. https://doi.org/10.1186/s12885-018-4932-2CrossRefPubMedPubMedCentral

63.

Cadron I, Amant F, Van Gorp T, Neven P, Leunen K, Vergote I (2006) The management of borderline tumours of the ovary. Curr Opin Oncol 18(5):488–493. https://doi.org/10.1097/01.cco.0000239889.98289.ceCrossRefPubMed

64.

Jiao X, Hu J, Zhu L (2017) Prognostic factors for recurrence after fertility-preserving surgery in patients with borderline ovarian tumors: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 27(9):1833–1841. https://doi.org/10.1097/igc.0000000000001092CrossRef

65.

Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A (2006) Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol 100(1):185–191. https://doi.org/10.1016/j.ygyno.2005.09.021CrossRefPubMed

66.

Morice P, Uzan C, Fauvet R, Gouy S, Duvillard P, Darai E (2012) Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol 13(3):e103–e115. https://doi.org/10.1016/s1470-2045(11)70288-1CrossRefPubMed

Titel: Unilateral cystectomy and serous histology are associated with relapse in borderline ovarian tumor patients with fertility-sparing surgery: a systematic review and meta-analysis
verfasst von: Na Li
Xiu Ming
Zhengyu Li
Publikationsdatum: 03.08.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 5/2020
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-020-05716-x

Adverse birth outcome across the generations: the contribution of paternal factors

Maternal-Fetal Medicine

Anti-retroviral therapy failure in HIV-1 infected pregnant women and its associated risk of HIV transmission

General Gynecology

Altered VEGF, Bcl-2 and IDH1 expression in patients with adenomyosis

General Gynecology

The reproductive prognosis of women considering fertility preservation for early stage endometrial cancer

Correspondence

Risk of systemic lupus erythematosus in patients with endometriosis: A nationwide population-based cohort study

General Gynecology

MiRNAs expression profiling of rat ovaries displaying PCOS with insulin resistance

Open Access
General Gynecology

Neu im Fachgebiet Gynäkologie und Geburtshilfe

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Einer von sieben Frauen macht die Menopause sehr zu schaffen

15.01.2025
Menopause
Nachrichten

Von mäßigen bis schweren vasomotorischen Beschwerden sind 14,7% der Frauen in der Postmenopause betroffen. Das haben kanadische Forscherinnen in einer Subgruppenanalyse der WARM-Studie herausgefunden.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

12.01.2025
Elektronische Patientenakte
Nachrichten

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Keine eingeschränkten Kassenleistungen bei Schwangerschaft nach IVF

Medikamente in Schwangerschaft und Stillzeit
Nachrichten

Nach privat bezahlter In-vitro-Fertilisation muss die gesetzliche Krankenkasse ein Arzneimittel zum Erhalt der Schwangerschaft bezahlen, so ein Urteil des Sozialgerichts in München.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Unilateral cystectomy and serous histology are associated with relapse in borderline ovarian tumor patients with fertility-sparing surgery: a systematic review and meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

Weitere Artikel der Ausgabe 5/2020

Adverse birth outcome across the generations: the contribution of paternal factors

Anti-retroviral therapy failure in HIV-1 infected pregnant women and its associated risk of HIV transmission

Altered VEGF, Bcl-2 and IDH1 expression in patients with adenomyosis

The reproductive prognosis of women considering fertility preservation for early stage endometrial cancer

Risk of systemic lupus erythematosus in patients with endometriosis: A nationwide population-based cohort study

MiRNAs expression profiling of rat ovaries displaying PCOS with insulin resistance

Neu im Fachgebiet Gynäkologie und Geburtshilfe

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Einer von sieben Frauen macht die Menopause sehr zu schaffen

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Keine eingeschränkten Kassenleistungen bei Schwangerschaft nach IVF

Update Gynäkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten